No one knows for sure why these disparities exist. But a likely explanation is that the higher rates are seen among groups of people with more risk factors.

This vaccine is unavailable and out-of-reach financially in rural Africa and Asia, which is why chronic hepatitis B rates remain stubbornly high and are projected to remain unchanged.